Akebia Therapeutics Abandons Vafseo Expansion Trial After FDA Disagreement on Study Design
核心洞察
Akebia Therapeutics has decided not to initiate the VALOR clinical trial for Vafseo in non-dialysis chronic kidney disease patients after failing to reach alignment with the FDA on study design.
The FDA indicated that regulatory approval would require a significantly larger patient population than Akebia proposed, leading to substantially increased time and costs for the trial.
The company will focus on making Vafseo the standard of care for dialysis patients while exploring potential trials in smaller CKD patient subgroups.
Akebia Therapeutics announced on October 28, 2025, that it will not proceed with the VALOR clinical trial designed to expand Vafseo's indication to non-dialysis chronic kidney disease (CKD) patients after failing to reach regulatory alignment with the U.S. Food and Drug Administration (FDA). The decision follows a Type C meeting where the FDA indicated that approval would require a significantly larger patient population than the company had proposed.
Regulatory Setback Forces Strategic Pivot
The Cambridge, Massachusetts-based biopharmaceutical company completed a face-to-face Type C meeting with the FDA, though final meeting minutes have not yet been received. Based on the regulatory feedback, Akebia believes that achieving alignment for the VALOR trial would require "meaningfully more time and cost to complete" due to the expanded patient enrollment requirements.
"Because we remain steadfast in our belief of the significant unmet need for an oral option to treat anemia in CKD patients not on dialysis, we are disappointed in the outcome of the meeting," said John P. Butler, Chief Executive Officer at Akebia. "We believe our decision not to pursue a broad NDD-CKD label, based on our discussion with the FDA, is in the best interests of our shareholders."
Current Market Position and Future Strategy
Vafseo (vadadustat) is currently approved in the United States for treating anemia due to CKD in adults who have been receiving dialysis for at least three months. Nephrologists began prescribing the oral medication to patients in January 2025. The drug is also approved for use in 37 countries worldwide.
Despite the setback with the broad non-dialysis indication, Butler indicated that the FDA discussions revealed potential opportunities in smaller CKD patient subgroups. "We were encouraged by the discussion with FDA on smaller subgroups of CKD patients where we may be able to align on a potential clinical trial design and path forward," he stated.
Mechanism of Action and Safety Profile
Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (搜索) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia.
The drug carries a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access. Clinical data shows that targeting hemoglobin levels greater than 11 g/dL is expected to further increase these risks, similar to erythropoietin stimulating agents.
Safety Concerns in Non-Dialysis Population
The FDA's prescribing information specifically states that Vafseo's safety has not been established for treating anemia due to CKD in adults not on dialysis, and its use is not recommended in this setting. In large clinical trials involving non-dialysis CKD patients, an increased risk of mortality, stroke, myocardial infarction, serious acute kidney injury, serious hepatic injury, and serious gastrointestinal erosions was observed in patients treated with Vafseo compared to darbepoetin alfa.
The most common adverse reactions occurring in at least 10% of patients were hypertension and diarrhea. Hepatocellular injury attributed to Vafseo was reported in less than 1% of patients, with elevated serum ALT, AST, and bilirubin levels observed in 1.8%, 1.8%, and 0.3% of CKD patients, respectively.
Strategic Focus on Dialysis Market
Moving forward, Akebia will concentrate its efforts on establishing Vafseo as the standard of care for patients on dialysis. The company maintains its commitment to addressing kidney disease, having been founded in 2007 with the specific purpose of improving lives for people impacted by this condition.
The decision to abandon the broad non-dialysis indication represents a significant strategic shift for Akebia, as the company weighs the substantial regulatory requirements against shareholder interests and available resources.